Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biosensor Platform Developed for POC Diagnosis of Cerebrovascular Disease

By LabMedica International staff writers
Posted on 27 Apr 2011
A consortium has been formed to develop an immunoassay detection device for the diagnosis of cerebrovascular disease. More...


The device has to be standalone so that it may be used for emergencies such as when diagnosis is required in an ambulance, emergency room, or as part of a rapid near-patient laboratory test in a hospital environment. Therefore, a number of key processes must be completed automatically within the system. The biosensor platform needs to be able to manipulate liquid samples and deliver any biomarkers that are present to the surface of the sensor in a manner that ensures accurate and reliable detection.

The EUR 3.6-million P3SENS consortium project, which is being coordinated by Multitel (Mons, Belgium), has been making good progress. The aim of the project is to design, develop, and manufacture robust microfluidic systems that can be used for fast and cost-effective sample transport and that also contain simple sample preparation functions.

Preliminary microfluidic structures have been designed taking into consideration the proposed layout of the sensor chip and the material requirements. The microfluidics system is to contain six parallel individual channels with different components supplying the integrated functions of washing and mixing.

Members of the consortium include: The Research Institute for Technical Physics and Materials Science (MFA, Budapest Hungary), which is mainly responsible for the immobilization and optical characterization of receptor protein layers using label-free optical waveguide based sensors, and for the manufacture of the microfluidic polymer structure; and a Center for Micro and Nanotechnology located in Micronova (Finland) and run jointly by VTT Technical Research Center of Finland (VTT; Finland) and Aalto University (Finland). VTT's main responsibilities in the project are the development of nanoimprint lithography (NIL) for patterning waveguides and photonic crystals into the polymer, the design and fabrication of NIL-based photonic chips, and the integration of photonic and fluidic functions in a single chip. Other institutes in the consortium include The Biomedical Proteomics Research Group (BPRG) at Geneva University (Switzerland); The James Watt Nanofabrication Center (JWNC) in Glasgow University (Scotland); Bayer Technology Services GmbH (Leverkusen, Germany); and Stratophase, a VC-funded spin-out from the University of Southampton in (UK).

Related Links:

P3SENS consortium project
Multitel
The Research Institute for Technical Physics and Materials Science
Center for Micro and Nanotechnology
VTT Technical Research Center of Finland
Aalto University
Biomedical Proteomics Research Group (BPRG) at Geneva University
The James Watt Nanofabrication Center (JWNC) in Glasgow University
Bayer Technology Services GmbH
Stratophase



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.